PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Clinical trials for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA explained in plain language.
Never miss a new study
Get alerted when new PAROXYSMAL NOCTURNAL HEMOGLOBINURIA trials appear
Sign up with your email to follow new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for PNH patients: LP-005 Long-Term safety trial begins
Disease control Not yet recruitingThis study is for people with PNH who already finished a previous LP-005 trial. It will check if the drug is safe and works well over a longer time. About 30 adults will take part. The goal is to control the disease and reduce symptoms like fatigue and blood clots.
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated May 26, 2026 08:02 UTC
-
New pill shows promise for rare blood disorder in Long-Term trial
Disease control Not yet recruitingThis study looks at the long-term safety and effectiveness of NTQ5082 capsules for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. About 78 adults who have already benefited from NTQ5082 or are on a standard treatment wi…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Phase: PHASE3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated May 26, 2026 08:00 UTC
-
New hope for PNH patients: experimental drug NM8074 aims to improve treatment
Disease control Not yet recruitingThis study tests a new drug called NM8074 in 12 adults with paroxysmal nocturnal hemoglobinuria (PNH) who are currently taking Soliris. The goal is to see if NM8074 is safe and works better at controlling the disease. Participants will receive NM8074 while doctors monitor side ef…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Phase: PHASE2 • Sponsor: NovelMed Therapeutics • Aim: Disease control
Last updated May 26, 2026 07:58 UTC
-
New pill could help PNH patients avoid blood transfusions
Disease control Not yet recruitingThis Phase 3 study tests an experimental oral drug, NTQ5082, for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The goal is to see if the drug can raise hemoglobin levels enough to avoid blood transfusions. About 78 adu…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Phase: PHASE3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated May 26, 2026 07:55 UTC
-
New drug under watch: Fabhalta's Real-World safety tracked in korea
Disease control Not yet recruitingThis study is a safety check on the drug Fabhalta (iptacopan) for Korean adults with two rare diseases: paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder, and C3 glomerulopathy (C3G), a kidney disease. Researchers will track side effects and lab results from up to 21 pa…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 07:53 UTC